Nemaura Medical Investor Presentation Deck

B Good morning, Samantha Time 09:03 Today 6.2 sugor BEAT ↑ 2 10.6 94 6.5 6.2 Future targets.. TARGET: Obtain FDA approval for sugarBEATⓇ TARGET: Scale-up manufacture to support sales in UK, Europe & and Middle East through licensees TARGET: Build market share in USA with employers and insurers, for the BEAT diabetes and Miboko (non-medical) programs. Scaled-up Pilot programs in June 2023. TARGET: Launch sugarBEAT® 'Direct-to-Consumer' in all major territories accepting CE approval as part of product registration; Discussions in multiple territories ongoing TARGET: Commercial exploitation of the metabolic health and wellbeing market using the sensors, initially targeting over 87 million people in the USA with pre- diabetes¹

View entire presentation